China CAR-T Cell

Currently, the cost is high because each patient’s CAR-T cells have to be produced individually. In addition to the preliminary research and development expenses, after the listing in the United States, the price is more than 2 million yuan(Chinese currency). Even if you move to China, the cost will be several hundred thousand, so it is not surprising to be sold at 1.2 million.

Although 1.2 million is high enough to buy a house in a small city, industry insiders said: This price is quite conscientious, compared to US$373,000 (2.42 million yuan) in the United States and US$305,000 (1.98 million yuan) in Japan. It is very cheap, very much.

Let’s compare the prices of several foreign CAR-T therapies, and you will know that 1.2 million injections are the cheapest.

1. Yescarta in China: 1.2 million yuan/$190,000

Yescarta approved in China is mainly indicated for adult patients with relapsed and refractory large B-cell lymphoma after second-line or more systemic therapy. The drug was approved for marketing in China on June 22, 2021.

2. Kymriah: $475,000

Kymriah was approved by the FDA on August 30, 2017. It is mainly used for adolescents and children, and has good effects on relapsed, refractory, and juvenile B-cell acute lymphoblastic leukemia.

3. Yescarta: $373,000

Yescarta was approved for marketing on October 18, 2017. For relapsed, refractory, specific types of adult large B-cell lymphoma, this is the first CAR-T drug mainly targeting non-Hodgkin lymphoma.

4. Tecartus: $373,000

Tecartus was approved for marketing in July 2020, mainly for patients with relapsed and refractory mantle cell lymphoma. This is the first CAR-T therapy approved for mantle cell lymphoma.

5. Breyanzi: $410,300

Breyanzi was approved for marketing in February 2021 for the treatment of selected adult patients with large B-cell lymphoma who have not responded to at least 2 other systemic therapies or have relapsed after treatment.

6. Abecma: $419,500

Abecma was approved for marketing in March 2021 for the treatment of patients with relapsed and refractory multiple myeloma who have undergone 4 or more advanced therapies. This is the first FDA-approved BCMA-targeting CAR-T therapy.

It can be seen that for CAR-T cell therapy, high cost and price seem to be inevitable. However, in the face of a million-dollar price, once it becomes a “money-burning” treatment, how many patients can afford this is a worrying question. Of course, we still have solutions here like some trials. CAR-T cell preparation free. You may send us the medical docs for the better solution.

One more thing. Can this treatment cure all cancers?

There is no cure for all diseases in the world, and the same is true for cancer!

Many domestic oncologists have emphasized that CAR-T cell therapy is not a panacea for oncology. At present, this therapy mainly treats tumors of the blood system.

“For example, leukemia, lymphoma, and multiple myeloma have relatively good treatment effects, but the effect on other cancers is less certain.”